Professor Daniele Avenoso is Associate Professor of Hematology at the University of Brescia and the Civil Hospitals of Brescia, Italy, where he also serves as Director of the Postgraduate School of Hematology. He holds deep expertise in hematology, with a particular focus on allogeneic stem cell transplantation and cellular therapies. Prof. Avenoso earned his PhD in Translational Hematology from the University of Genoa and has acquired extensive international clinical and research experience, notably during his tenure at King’s College Hospital. His clinical and scientific interests are centered on the complex management of hematological diseases, with a special emphasis on chronic graft-versus-host disease (GVHD) and thrombotic microangiopathy (TMA) following allogeneic hematopoietic stem cell transplantation. He has played a key role in multiple clinical trials and has authored numerous publications in leading peer-reviewed journals, contributing significantly to the advancement of stem cell transplantation, immunotherapy, GVHD, and transplant-associated TMA.

I am a clinical hematologist with a strong background in high-level research since my medical studies at the University of Pavia. My main scientific contribution has been integrating single-cell transcriptomics and genomic sequencing to dissect hematological disease architecture and evolution after treatment. Under Prof. Mario Cazzola and Luca Malcovati, I explored SF3B1 mutations in myelodysplastic syndromes, now included in WHO/ICC classifications. At Würzburg University Hospital (2016-2019), I identified PSMB5 mutations as drivers of MM therapy resistance and uncovered RAS/RAF pathway dysregulation in CNS-MM. Recently, I described a novel immune escape mechanism in anti-BCMA CAR T therapy. Since 2019, I have been working with Prof. Niccolò Bolli at the University of Milan on the ERC-funded “BeCOMiNg” project, studying MM preclinical phases with multi-omics approaches. My research focuses on MM predictive models, integrating clinical practice with global collaborations to establish myself as an independent investigator.

I am an Associate Professor of Hematology at the University of Genoa and Associate Director of the Multiple Myeloma Program at San Martino Hospital. My research focuses on the pathobiology of multiple myeloma, the molecular mechanisms of novel anticancer therapies, and the identification of genetic vulnerabilities that can be therapeutically exploited. I combine oncogenomic and functional approaches to uncover mechanisms of resistance and develop rational, targeted treatment strategies to improve outcomes for patients with high-risk myeloma. I received training and conducted research at leading international institutions, including the Dana-Farber Cancer Institute and EPFL Lausanne, and I am an active member of the European Myeloma Network.